These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17141978)

  • 21. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
    Bardet E; Martin L; Calais G; Alfonsi M; Feham NE; Tuchais C; Boisselier P; Dessard-Diana B; Seng SH; Garaud P; Aupérin A; Bourhis J
    J Clin Oncol; 2011 Jan; 29(2):127-33. PubMed ID: 21115863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
    Thorstad WL; Haughey B; Chao KS
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
    Anacak Y; Kamer S; Haydaroglu A
    Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amifostine-induced fever: case report and review of the literature.
    Boehme S; Wilson DB
    Pharmacotherapy; 2004 Jan; 24(1):155-8. PubMed ID: 14740795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New data on cytoprotection in radiotherapy].
    Sauer R; Strnad V
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
    [No Abstract]   [Full Text] [Related]  

  • 31. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
    Trog D; Bank P; Wendt TG; Koscielny S; Beleites E
    Strahlenther Onkol; 1999 Sep; 175(9):444-9. PubMed ID: 10518978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
    Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
    Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
    Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
    Gu J; Zhu S; Li X; Wu H; Li Y; Hua F
    PLoS One; 2014; 9(5):e95968. PubMed ID: 24788761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J; Küttner K; Fröhlich D; Glatzel M
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiochemotherapy with amifostine cytoprotection for head and neck cancer.
    Büntzel J; Schuth J; Küttner K; Glatzel M
    Support Care Cancer; 1998 Mar; 6(2):155-60. PubMed ID: 9540175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine].
    Schultze J; Kimmig B
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():13-7. PubMed ID: 10584134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.